Physiomics Regulatory News (PYC)

23 Jun 2005 06:00

Physiomics and Bayer Technology Services sign UK distribution agreement for PK-Sim‚® Oxford, UK and Leverkusen, Germany 23rd June 2005 Physiomics (AIM: PYC) andBayer Technology Services GmbH (BTS) have signed an agreement under which BTShas appointed Physiomics as a distributor of its PK-Sim‚® pharmacokineticmodelling products and services for a renewable five-year period. Theagreement, which covers all therapeutic areas, should also enable increasedsales of the Clinical Response Prediction system, which combines PK-Sim withPhysiomics' pharmacodynamic SystemCell‚® technology.Physiomics and BTS believe that advanced whole body simulations can optimisethe transition from preclinical to clinical development and help in theoptimisation of dose scheduling, one of the major problems in clinical trialdesign. Studies1 have shown that improving the drug development success rate by10% overall could save $242m per drug. Under a separate global deal announcedin September 2004, Physiomics and Bayer collaborate on Clinical ResponsePrediction in the area of cancer.Physiomics will initially develop the UK market for PK-Sim and act as theprimary customer interface. Financial terms of the agreement were notdisclosed.Dr Stephen Parker, Chairman of Physiomics, commented: "We are delighted tofurther our relationship with Bayer. This is an important achievement for theCompany as it extends and diversifies our product base and range of businessdevelopment opportunities. The new distributor agreement will enable us to workon all therapeutic areas with a very sophisticated service and productoffering, and should have a positive impact on Clinical Response Predictionsales."1 Tufts Center Impact Report 2002 --ENDS- For further information please contact: Physiomics plcDr Stephen Parker (Chairman) Tel: 07771 526 785Dr John Savin (CEO) Tel: 01865 784 980 Northbank Communications Tel: 020 7886 8150Emma PalmerFiona BrownRowan MinnionNotes to EditorsPhysiomics plcPhysiomics plc, founded in 2001, develops and sells services aimed at reducingthe high cost of drug development for pharmaceutical and biotechnologycompanies by optimising the design of cancer clinical trials through theapplication of computer-based simulations. Physiomics is also applying itstechnologies to develop proprietary cancer therapy products for out-licensingand, to this end, it has secured an option to license two innovative molecules.For more information go to www.physiomics-plc.comSystemCell is a registered trademark of Physiomics plcBayer Technology Services GmbHBayer Technology Services GmbH is the center for technological competence ofthe Bayer Group worldwide. The Bayer company employs more than 2,100 expertsworldwide at its headquarters in Leverkusen and other German locations, as wellas in regional offices in Baytown (Texas, USA), Antwerp (Belgium), Mexico City(Mexico) and Shanghai (Peoples Republic of China). Bayer Technology Servicesposted sales of EUR 520 million in 2004, including utilities procurement forall Bayer sites in Germany (first six month only). In addition tofully-integrated solutions along the life cycle of pharmaceutical and chemicalplants - from development through engineering and construction to processoptimization, Bayer Technology Services offers a broad range of products andservices for all stages of diagnostics and drug research and development.Examples include nano-phosphors, the pharmacokinetic simulation software PK-Sim‚® as well as sophisticated data mining and modeling techniques. Additionalinformation about Bayer Technology Services is available at www.bayertechnology.com.PK-Sim is a registered trademark of Bayer Technology Services GmbH Physiomics plc Registered in England and Wales Number 4225086 Registered Office: The Magdalen Centre, Oxford Science Park, Oxford OX4 4GA, UKENDPHYSIOMICS PLC